Last Updated: 16 Sep 2024
Executive Summary
INmune Bio Inc. (INMB) is a clinical-stage immunotherapy company with a market capitalization of approximately $108 million. The company is focused on developing treatments for cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. INMB's latest stock price is $5.46, which is below its 52-week high of $14.74. Analysts have a mixed view on the stock, with two analysts rating it a "Strong Buy" and one rating it a "Buy." The company has a trailing EPS of -$2.05 and a price-to-sales ratio of 1270.73.
Company Overview
INmune Bio Inc. was founded in 2010 and is headquartered in La Jolla, California. The company's lead product candidate is INB-001, a monoclonal antibody that targets the CD122 receptor on immune cells. INB-001 is currently being evaluated in clinical trials for the treatment of several types of cancer. The company also has a pipeline of other product candidates in preclinical development.
Fundamental Analysis
INmune Bio Inc.'s financial performance has been mixed in recent quarters. The company reported a net loss of $25.2 million in the first half of 2023, compared to a net loss of $16.4 million in the first half of 2022. Revenue for the first half of 2023 was $85,000, compared to $227,000 in the first half of 2022. The company's cash and cash equivalents were $47.2 million as of June 30, 2023.
Technical Analysis
INmune Bio Inc.'s stock price has been trending lower in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
The short-term outlook for INmune Bio Inc. is mixed. The company's stock price is trading below its 50-day and 200-day moving averages, and the RSI is below 50. This indicates that the stock could continue to trend lower in the short term. However, the company has a strong pipeline of product candidates and a significant amount of cash on hand. This could provide support for the stock price in the long term.
Long Term Outlook
The long-term outlook for INmune Bio Inc. is positive. The company's lead product candidate, INB-001, has shown promising results in clinical trials. If INB-001 is approved by the FDA, it could be a major commercial success for the company. INmune Bio Inc. also has a pipeline of other product candidates in preclinical development. These candidates could provide additional revenue streams for the company in the future.
Analyst Recommendations
Analysts have a mixed view on INmune Bio Inc. Two analysts rate the stock a "Strong Buy" and one analyst rates it a "Buy." The average analyst target price is $20.25, which is significantly higher than the current stock price.
